Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
BMC Psychiatry|February 9, 2011
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysisIbrahim Turkoz, Cynthia A Bossie, Jean-Pierre Lindenmayer, et al.
The Journal of Clinical Psychiatry|September 26, 2009
Outcome evaluation of a structured educational wellness program in patients with severe mental illnessJean-Pierre Lindenmayer, Anzalee Khan, Deborah Wance, et al.
The Journal of the American Academy of Psychiatry and the Law|June 30, 2005
A cognitive, behaviorally based program for patients with persistent mental illness and a history of aggression, crime, or both: structure and correlates of completers of the programKathy Yates, Michal Kunz, Pal Czobor, et al.
Schizophrenia Research|August 6, 2013
A new Integrated Negative Symptom structure of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia using item response analysisAnzalee Khan, Jean-Pierre Lindenmayer, Mark Opler, et al.
Psychopathology|April 29, 2008
Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scaleJean-Pierre Lindenmayer, Cynthia A Bossie, Mary Kujawa, et al.
International Clinical Psychopharmacology|June 4, 2005
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidoneJean-Pierre Lindenmayer, Kathleen Jarboe, Cynthia A Bossie, et al.
Psychiatric Services (Washington, D.C.)|June 4, 2004
Course of patients with histories of aggression and crime after discharge from a cognitive-behavioral programMichael Kunz, Kathy F Yates, Pal Czobor, et al.
Schizophrenia Research|April 30, 2017
Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, David Walling, et al.
The American Journal of Psychiatry|June 5, 2003
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychoticJohn M Kane, Mariëlle Eerdekens, Jean-Pierre Lindenmayer, et al.
Schizophrenia Research. Cognition|December 13, 2019
Differential improvement of negative-symptom subfactors after cognitive remediation in low-functioning individuals with schizophreniaSerge Sevy, Jean-Pierre Lindenmayer, Anzalee Khan, et al.
Pageof 10